Company intelligence / Profile preview

Target2Drug BioAdvisory

California, United Statest2dbioadvisory.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Target2Drug BioAdvisory is a boutique strategic advisory firm founded in December 2022 by Songsong “David” Cao. It specializes in helping small biotech companies make smarter and faster decisions across the entire drug development lifecycle—from target identification through commercialization. The founder leverages over two decades of experience in both large pharma and startup environments to guide clients, particularly those with platform technologies.

Industry: Consulting

Beyond the preview

Go deeper on Target2Drug BioAdvisory.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target2Drug BioAdvisory.

Explore the full profile